Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem dose comparison in critically ill patients with hospital-acquired or ventilator-associated pneumonia
IRCT20100107003014N19Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of meropenem in bacterial pneumonia, hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Clinical success. Started Apr 2018; status: completed.
02
Drugs
meropenem
03
Conditions
bacterial pneumoniahospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20100107003014N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100107003014N19.